235 related articles for article (PubMed ID: 26289642)
1. The forkhead transcription factor FOXP1 represses human plasma cell differentiation.
van Keimpema M; Grüneberg LJ; Mokry M; van Boxtel R; van Zelm MC; Coffer P; Pals ST; Spaargaren M
Blood; 2015 Oct; 126(18):2098-109. PubMed ID: 26289642
[TBL] [Abstract][Full Text] [Related]
2. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of FOXP1 is required during germinal center B-cell function.
Sagardoy A; Martinez-Ferrandis JI; Roa S; Bunting KL; Aznar MA; Elemento O; Shaknovich R; Fontán L; Fresquet V; Perez-Roger I; Robles EF; De Smedt L; Sagaert X; Melnick A; Martinez-Climent JA
Blood; 2013 May; 121(21):4311-20. PubMed ID: 23580662
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.
van Keimpema M; Grüneberg LJ; Mokry M; van Boxtel R; Koster J; Coffer PJ; Pals ST; Spaargaren M
Blood; 2014 Nov; 124(23):3431-40. PubMed ID: 25267198
[TBL] [Abstract][Full Text] [Related]
5. N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
Brown PJ; Gascoyne DM; Lyne L; Spearman H; Felce SL; McFadden N; Chakravarty P; Barrans S; Lynham S; Calado DP; Ward M; Banham AH
Haematologica; 2016 Jul; 101(7):861-71. PubMed ID: 27056922
[TBL] [Abstract][Full Text] [Related]
6. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.
Vogel MJ; Xie L; Guan H; Tooze RM; Maier T; Kostezka U; Maier HJ; Holzmann K; Chan FC; Steidl C; Reichel JB; Weitzer CD; Gehringer F; Kick AB; Cesarman E; Roshal M; Gascoyne RD; Möller P; Wirth T; Ushmorov A
Blood; 2014 Nov; 124(20):3118-29. PubMed ID: 25232062
[TBL] [Abstract][Full Text] [Related]
7. FOXP1 inhibits plasma cell differentiation.
Toellner KM
Blood; 2015 Oct; 126(18):2076-7. PubMed ID: 26516214
[No Abstract] [Full Text] [Related]
8. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
[TBL] [Abstract][Full Text] [Related]
9. Loss of the FOXP1 Transcription Factor Leads to Deregulation of B Lymphocyte Development and Function at Multiple Stages.
Dekker JD; Baracho GV; Zhu Z; Ippolito GC; Schmitz RJ; Rickert RC; Tucker HO
Immunohorizons; 2019 Oct; 3(10):447-462. PubMed ID: 31591252
[TBL] [Abstract][Full Text] [Related]
10. FOXP1 is a regulator of quiescence in healthy human CD4
Garaud S; Roufosse F; De Silva P; Gu-Trantien C; Lodewyckx JN; Duvillier H; Dedeurwaerder S; Bizet M; Defrance M; Fuks F; Bex F; Willard-Gallo K
Eur J Immunol; 2017 Jan; 47(1):168-179. PubMed ID: 27861791
[TBL] [Abstract][Full Text] [Related]
11. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
12. IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
Teng Y; Takahashi Y; Yamada M; Kurosu T; Koyama T; Miura O; Miki T
Eur J Cell Biol; 2007 Oct; 86(10):581-9. PubMed ID: 17651861
[TBL] [Abstract][Full Text] [Related]
13. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
15. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1.
Rao DS; O'Connell RM; Chaudhuri AA; Garcia-Flores Y; Geiger TL; Baltimore D
Immunity; 2010 Jul; 33(1):48-59. PubMed ID: 20598588
[TBL] [Abstract][Full Text] [Related]
17. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
18. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
19. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.
De Silva P; Garaud S; Solinas C; de Wind A; Van den Eyden G; Jose V; Gu-Trantien C; Migliori E; Boisson A; Naveaux C; Duvillier H; Craciun L; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
EBioMedicine; 2019 Jan; 39():226-238. PubMed ID: 30579865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
